K-LYTE/CL 50 Rx
Generic Name and Formulations:
Potassium (as chloride) 50mEq; effervescent tabs for soln; citrus and fruit-flavor.
- Oral Micronized Progesterone May Decrease Perimenopausal Vasomotor Symptoms
- Abatacept May Improve Femoral Neck Bone Mineral Density in Rheumatoid Arthritis
- Increased Risk for Severe Hypoglycemic Events Associated With CV Outcomes
Indications for K-LYTE/CL 50:
Hypokalemia, including that caused by diuretics. Digitalis intoxication without AV block.
Prophylaxis: 25mEq daily. Treatment: 50–100mEq daily in divided doses. Both, dissolve each tab in 6–8oz of water and sip slowly over 5–10 minutes after meals.
Hyperkalemia. Chronic renal disease. Acute dehydration. Heat cramps. Severe tissue destruction. Adrenal insufficiency. Familial periodic paralysis. Acidosis (potassium chloride products). Alkalosis (potassium bicarbonate products). Tablets: Esophageal compression due to enlarged left atrium. Decreased GI motility.
Discontinue if GI bleed, ulceration, or other disturbances occur. Renal or cardiac disease. Monitor potassium level, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers.
Hyperkalemia with ACE inhibitors, spironolactone, triamterene, amiloride, and potassium-containing salt substitutes. Anticholinergics, other agents that decrease GI motility increase risk of serious GI reactions with tablets.
Hyperkalemia, GI discomfort and irritation, diarrhea, rash (rare). Tablets: Esophageal and GI ulceration, bleeding, obstruction, perforation.
K-Lyte/Cl tabs—30, 100, 250; K-Lyte/Cl 50 tabs—30, 100
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Reducing Total Daily Insulin Dose in T2D: 3-Meal vs 6-Meal Diet
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Metformin May Improve Pregnancy Outcomes in Polycystic Ovary Syndrome
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure